MedTrace Logo

A Study of STP707 Administered by IV in Healthy Subjects

NCT05309915 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-03-18

No results posted yet for this study

Summary

Single center study, randomized, to evaluate safety, tolerability, PK of single ascending dose of STP707 when administered by IV infusion in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

STP707

STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Sirnaomics

    lead INDUSTRY

Principal Investigators

  • Francois Lebel, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-08-30
Completion
2022-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05309915 on ClinicalTrials.gov